Structure Therapeutics (GPCR, Financial) has received a revised price target from HC Wainwright & Co. Analyst Andrew Fein maintained a "Buy" rating for the stock but lowered the price target from USD 80.00 to USD 75.00. The action reflects a 6.25% decrease in the anticipated target price.
The updated price target for GPCR comes as HC Wainwright & Co. continues to support the potential of Structure Therapeutics by maintaining its "Buy" rating. The firm has consistently advocated for the prospects of GPCR in its analytical assessments.
Investors are encouraged to note these developments as HC Wainwright & Co. remains optimistic about the future performance of Structure Therapeutics, as indicated by the retention of their favorable "Buy" rating, despite the adjusted price target.
The revised price target and maintained rating by HC Wainwright & Co. were announced on May 12, 2025. The changes are significant for market participants closely monitoring GPCR's potential in delivering value within the competitive landscape.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 14 analysts, the average target price for Structure Therapeutics Inc (GPCR, Financial) is $79.00 with a high estimate of $120.00 and a low estimate of $50.00. The average target implies an upside of 208.96% from the current price of $25.57. More detailed estimate data can be found on the Structure Therapeutics Inc (GPCR) Forecast page.
Based on the consensus recommendation from 14 brokerage firms, Structure Therapeutics Inc's (GPCR, Financial) average brokerage recommendation is currently 1.6, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
